Eli Lilly Partners with METiS Pharmaceuticals on AI-Driven LNP Delivery Platform
Start here
METiS Pharmaceuticals (7666.HK), also known as Jitai Tech, has entered a strategic collaboration with Eli Lilly centered on its AI-driven lipid nanoparticle (LNP) delivery platform, AiLNP. METiS will be responsible for ionizable lipid discovery and optimizing targeted LNP delivery, while Lilly brings drug discovery, development and commercialization resources. The agreement includes an upfront payment of over $10 million, and METiS is eligible for up to $1.1 billion in development, regulatory and commercial milestone payments, plus tiered single-digit percentage royalties on annual net sales of collaboration products. According to public deal records, this is the first strategic collaboration in China centered on a generative AI platform for LNP delivery, and one of the largest AI-driven extrahepatic LNP delivery platform deals globally.
Written by a model from the reports · updated 26 min ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatMETiS Pharmaceuticals and Eli Lilly Strike Strategic Deal on Tissue-Specific LNP Delivery Technology
METiS Pharmaceuticals (7666.HK) has announced a strategic collaboration with Eli Lilly focused on tissue-specific LNP (lipid nanoparticle) delivery technology, jointly discovering and optimizing next-generation delivery solutions. Under the agreement, METiS will receive an upfront payment of over ten million US dollars, plus development, regulatory and commercial milestone payments totaling up to 1.1 billion US dollars, along with tiered royalties in the single-digit percentages based on annual net sales of collaboration products.
- bydrug.pharmcube.comPickMETiS Pharmaceuticals and Eli Lilly Strike $1.1 Billion AI-LNP Delivery Platform Collaboration
METiS Pharmaceuticals (7666.HK) announced a strategic collaboration with Eli Lilly worth up to $1.1 billion in total, focused on developing LNP delivery solutions based on generative AI. METiS will use its NanoForge-driven AiLNP platform to develop next-generation delivery technologies, while Lilly contributes drug discovery, development and commercialization resources, aiming to support tissue-specific delivery across multiple therapeutic modalities.
- bydrug.pharmcube.comPickMETiS Pharmaceuticals and Eli Lilly Sign LNP Delivery Deal with Over $10 Million Upfront and Up to $1.1 Billion Milestones
METiS Pharmaceuticals announced a strategic collaboration with Eli Lilly focused on research and discovery of novel LNP delivery solutions, exploring tissue-specific delivery supporting multiple therapeutic modalities. Under the agreement, METiS will receive an upfront payment of over $10 million and is eligible for development, regulatory and commercial milestone payments of up to $1.1 billion, plus tiered royalties at a single-digit percentage of annual net sales.
- WeChatPickMeticha Joins Eli Lilly in Strategic AI-LNP Delivery Platform Deal with Over $10 Million Upfront and Up to $1.1 Billion Milestones
Meticha (Jitai Tech) announced a strategic collaboration with Eli Lilly on its AI-driven LNP delivery platform AiLNP. Meticha will handle ionizable lipid discovery and LNP targeted-delivery optimization, while Lilly contributes drug discovery, development and commercialization resources. The deal includes an upfront payment of over $10 million, and Meticha is eligible for up to $1.1 billion in development, regulatory and commercial milestone payments. According to public deal records, this is the first strategic collaboration in China centered on a generative AI platform for LNP delivery, and one of the largest AI-driven extrahepatic LNP delivery platform deals globally.
Coverage and heat for this story
Reports so far 4·Heat now 8·Peak heat 10 (Oct 19 19:00)·Reports, 24h +4
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.